Tumor cavitation in stage I non-small cell lung cancer: Epidermal growth factor receptor expression and prediction of poor outcome

Radiology

Volumn 237, Issue 1, 2005, Pages 342-347

  Onn, Amir ^a   Choe, Du Hwan ^a   Herbst, Roy S ^a   Correa, Arlene M ^a   Munden, Reginald F ^a   Truong, Mylene T ^a   Vaporciyan, Ara A ^a   Isobe, Takeshi ^a   Gilcrease, Michael Z ^a   Marom, Edith M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC IMAGING; DISEASE COURSE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CAVITATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOGRAPHY, THORACIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 25144490101     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2371041650     Document Type: Article

References (26)

1. Carney DN. Lung cancer: time to move on from chemotherapy. N Engl J Med 2002; 346:126-128.
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
3. Massarelli E, Onn A, Zinner R, Khuri FR, Kim ES, Herbst RS. New targets for the treatment of advanced non-small cell lung cancer. Cancer Chemother Biol Response Modif 2002;20:717-761.
4. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-269.
5. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20(suppl 18):1S-13S.
6. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
7. Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004;10:136-143.
8. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-1987.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
10. Mouroux J, Padovani B, Elkaim D, Richelme H. Should cavitated bronchopulmonary cancers be considered a separate entity? Ann Thorac Surg 1996;61:530-532.
11. Kolodziejski LS, Dyczek S, Duda K, Goralczyk J, Wysocki WM, Lobaziewicz W. Cavitated tumor as a clinical subentity in squamous cell lung cancer patients. Neoplasma 2003;50:66-73
12. Mooi WJ. Common lung cancers. In: Hasleton PS, ed. Spencer's pathology of the lung. 5th ed. New York, NY: McGraw-Hill, 1996;1009-1064.
13. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
14. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidermal growth factor receptor family In lung cancer and premalignancy. Semin Oncol 2002;29:3-14.
15. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 1984;74:647-651.
16. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung, N Engl J Med 1990;323:561-565.
17. Herbst RS, Yano S, Kuniyasu H, et al. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000;6:790-797.
18. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-694.
19. Khuri FR, Lotan R, Kemp BL, et al. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 2000;18:2798-2804.
20. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A: a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 1991;324:1084-1090.
21. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
22. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
23. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
24. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
25. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-809.
26. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-261.